Diagnostic Efficacy of Gallium-PSMA-PET compared to Conventional Imaging in Lymph Node Staging of of 130 consecutive Patients with Intermediate to High-Risk Prostate Cancer.

Trial Profile

Diagnostic Efficacy of Gallium-PSMA-PET compared to Conventional Imaging in Lymph Node Staging of of 130 consecutive Patients with Intermediate to High-Risk Prostate Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2016

At a glance

  • Drugs Gallium 68 PSMA (Primary)
  • Indications Prostate cancer
  • Focus Diagnostic use
  • Most Recent Events

    • 30 Dec 2015 New trial record
    • 09 Dec 2015 Results published in the Journal of Urology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top